Impact of SSRI Therapy on Risk of Conversion From Mild Cognitive Impairment to Alzheimer’s Dementia in Individuals With Previous Depression
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Depression is associated with an increased risk of Alzheimer's disease. Research has shown that the selective serotonin reuptake inhibitor (SSRI) citalopram decreases amyloid-β generation and plaque load. The authors evaluated the impact of SSRI treatment on CSF biomarkers and progression from mild cognitive impairment (MCI) to Alzheimer's dementia. METHOD: Data sets from 755 currently nondepressed participants from the longitudinal Alzheimer's Disease Neuroimaging Initiative were evaluated by Kaplan-Meier analysis and analyses of variance and covariance with ApoE4 status and age as covariates. RESULTS: In MCI patients with a history of depression, long-term SSRI treatment (>4 years) was significantly associated with a delayed progression to Alzheimer's dementia by approximately 3 years, compared with short-term SSRI treatment, treatment with other antidepressants, or no treatment and compared with MCI patients without a history of depression. No differences in CSF biomarker levels were observed between treatment groups. CONCLUSIONS: Long-term SSRI treatment may delay progression from MCI to Alzheimer's dementia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The study found that more than 4 years of such treatment was associated with delayed progression to clinically diagnosed Alzheimer's disease.”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [119]
In the citing paper
“and long-term treatment with antidepressants delays the conversion of mild cognitive impairment to Alzheimer’s dementia119.”
From Mechanisms and treatment of late-life depression (2019) · cites this paper as [119]
In the citing paper
“Recent findings suggest that SSRIs may delay the onset of Alzheimer’s dementia119.”
From Mechanisms and treatment of late-life depression (2019) · cites this paper as [119]
Citations
Cites
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Diniz, B. S., Butters, M. A., Albert, S. M., Dew, M. A., & Reynolds, C. F. (2013) · British Journal of Psychiatry · doi:10.1192/bjp.bp.112.118307 · Cited by 1,290
Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C. R., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2005) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2005.06.003 · Cited by 1,233
Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975 · cited 1×
“A growing body of evidence points toward a complex role of neuroinflammation in amyloidogenesis, neurodegeneration, and cognitive decline (41).”
Setiawan, E., Wilson, A. A., Mizrahi, R., Rusjan, P. M., Miler, L., Rajkowska, G., Suridjan, I., Kennedy, J. L., Rekkas, P. V., Houle, S., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2427 · Cited by 939 · cited 1×
“Neuroinflammation has also been detected in patients during major depressive episodes (42, 43).”
Effect of Citalopram on Agitation in Alzheimer Disease: The CitAD Randomized Clinical Trial
Porsteinsson, A. P., Drye, L. T., Pollock, B. G., Devanand, D. P., Frangakis, C., Ismail, Z., Marano, C., Meinert, C. L., Mintzer, J. E., Munro, C. A., et al. (2014) · JAMA · doi:10.1001/jama.2014.93 · Cited by 572 · cited 1×
“Several randomized and placebocontrolled studies have evaluated the effect of SSRIs on cognition in Alzheimer’s dementia, finding either favorable effects (16, 17), no effects (18–20), or even disadvantageous effects of SSRI treatment (21, 22).”
Modrego, P. J., & Ferrández, J. (2004) · Archives of Neurology · doi:10.1001/archneur.61.8.1290 · Cited by 537 · cited 1×
“This is in contrast to anotherprospectivecohort (30) inwhichahigher rateofMCI progression to Alzheimer’s dementia was found to be associated with depression.”
Banerjee, S., Hellier, J., Dewey, M., Romeo, R., Ballard, C., Baldwin, R., Bentham, P., Fox, C., Holmes, C., Katona, C., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60830-1 · Cited by 532 · cited 1×
“Several randomized and placebocontrolled studies have evaluated the effect of SSRIs on cognition in Alzheimer’s dementia, finding either favorable effects (16, 17), no effects (18–20), or even disadvantageous effects of SSRI treatment (21, 22).”
Depressive symptoms, cognitive decline, and risk of AD in older persons
Wilson, R. S., Barnes, L. L., Mendes de Leon, C. F., Aggarwal, N. T., Schneider, J. S., Bach, J., Pilat, J., Beckett, L. A., Arnold, S. E., Evans, D. A., et al. (2002) · Neurology · doi:10.1212/wnl.59.3.364 · Cited by 528 · cited 1×
“Other studies have found that the severity of depression at baseline was correlated with risk of developing dementia (31).”
Research works printed but not linked: 1
- Bubu OM, Sleep
Cited by
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430
RetractedThe Epidemiology of Alzheimer's Disease Modifiable Risk Factors and Prevention
Zhang, X.-X., Tian, Y., Wang, Z.-T., Ma, Y.-H., Tan, L., & Yu, J.-T. (2021) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2021.15 · Cited by 789
“In addition, treatment with the citalopram for more than 4 years was strongly linked to a 3-year delay in progression from mild cognitive impairment (MCI) to AD (25).”
InfluentialMechanisms and treatment of late-life depression
Alexopoulos, G. S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0514-6 · Cited by 592
Microglia, Lifestyle Stress, and Neurodegeneration
Madore, C., Yin, Z., Leibowitz, J., & Butovsky, O. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.003 · Cited by 311
Depression—an underrecognized target for prevention of dementia in Alzheimer’s disease
Dafsari, F. S., & Jessen, F. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0839-1 · Cited by 312
Cognitive impairment and depression: Meta-analysis of structural magnetic resonance imaging studies
Zacková, L., Jáni, M., Brázdil, M., Nikolova, Y. S., & Marečková, K. (2021) · NeuroImage: Clinical · doi:10.1016/j.nicl.2021.102830 · Cited by 167
Depression in Alzheimer’s Disease: Epidemiology, Mechanisms, and Treatment
Huang, Y.-Y., Gan, Y.-H., Yang, L., Cheng, W., & Yu, J.-T. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.10.008 · Cited by 164
The synapse as a treatment avenue for Alzheimer’s Disease
Peng, L., Bestard‐Lorigados, I., & Song, W. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01565-z · Cited by 180
Voineskos, A. N., Mulsant, B. H., Dickie, E. W., Neufeld, N. H., Rothschild, A. J., Whyte, E. M., Meyers, B. S., Alexopoulos, G. S., Hoptman, M. J., Lerch, J. P., et al. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.0036 · Cited by 132
Chan, J. Y. C., Yiu, K. K. L., Kwok, T. C. Y., Wong, S. Y. S., & Tsoi, K. K. F. (2019) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2018.12.004 · Cited by 135
Gallagher, D., Kiss, A., Lanctot, K., & Herrmann, N. (2018) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2018.05.002 · Cited by 122
“In a recent longitudinal analysis in MCI patients with a history of depression, SSRI treatment for more than 4 years was significantly associated with delayed progression to Alzheimer’s dementia (32).”
BackgroundDepression and Dementia in Older Adults: A Neuropsychological Review
Tetsuka, S. (2021) · Aging and Disease · doi:10.14336/ad.2021.0526 · Cited by 129
“In a prospective longitudinal cohort study of patients with non-depression, long-term treatment (>4 years) with SSRIs in patients with MCI and a history of depression has been found to significantly delay the progression to AD by approximately 3 years; thus, long-term treatment with SSRIs might be capable of slowing t…”
BackgroundDiagnosing and Treating Depression in Patients with Alzheimer’s Disease
Burke, A. D., Goldfarb, D., Bollam, P., & Khokher, S. (2019) · Neurology and Therapy · doi:10.1007/s40120-019-00148-5 · Cited by 115
“[150] demonstrated that long-term SSRI treatment Neurol Ther (2019) 8:325–350 341”
BackgroundKwan, R. Y. C., Leung, A. Y. M., Yee, A., Lau, L. T., Xu, X., & Dai, D. (2019) · The journal of nutrition health & aging · doi:10.1007/s12603-019-1258-y · Cited by 111
Stress-Induced Depression and Alzheimer’s Disease: Focus on Astrocytes
Dolotov, O. V., Inozemtseva, L. S., Myasoedov, N. F., & Grivennikov, I. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094999 · Cited by 110
“The treatment of patients with depression and mild cognitive impairment (MCI) with SSRIs for more than 4 years delayed the progression of from MCI to AD by approximately 3 years compared to antidepressant-free patients or compared with MCI patients without a history of depression [77].”
ResultAgüera-Ortíz, L., García-Ramos, R., Pérez, F. J. G., López‐Álvarez, J., Rodríguez, J. M. M., Rodríguez, F. J. O., Pueyo, J. O., Valero, C. P., & Porta-Etessam, J. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.638651 · Cited by 95
“Long-term use of selective serotonin reuptake inhibitors (SSRIs) may delay dementia development in patients with MCI and depression (40).”
BackgroundSelective serotonin reuptake inhibitors and Alzheimer’s disease
Khoury, R., Mdawar, B., & Ghossoub, E. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.264445 · Cited by 84
“Interestingly, subjects who received SSRIs for more than 1610 days (defined by the authors as long term use) had a delay of 3 years in conversion to AD compared to subjects who took SSRIs for less than 1610 days: P = 0.008 (Bartels et al., 2018).”
BackgroundInfluentialTargeting NLRP3 inflammasome for neurodegenerative disorders
Yao, J., Wang, Z., Song, W., & Zhang, Y. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02239-0 · Cited by 86
Niculescu, A. B., Le-Niculescu, H., Roseberry, K., Wang, S., Hart, J., Kaur, A., Robertson, H., Jones, T., Strasburger, A., Williams, A., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0602-2 · Cited by 75
Health-Promoting Strategies for the Aging Brain
Chen, S. T., Volle, D. C., Jalil, J., Wu, P., & Small, G. W. (2018) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2018.12.016 · Cited by 75
Ng, K. P., Chiew, H. J., Rosa‐Neto, P., Kandiah, N., Ismail, Z., & Gauthier, S. G. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00236-3 · Cited by 74
“In addition, a study using ADNI data found that MCI subjects with a remote history of depression had a 3-year delay of progression to AD if they had been treated with selective serotonin reuptake inhibitors for more than four years [76].”
Serotonin, β‐amyloid, and cognition in Parkinson disease
Kotagal, V., Spino, C., Bohnen, N. I., Koeppe, R., & Albin, R. L. (2018) · Annals of Neurology · doi:10.1002/ana.25236 · Cited by 64
“Similar results were reported recently in a retrospective analysis of conversion from mild cognitive impairment to dementia in the Alzheimer Disease Neuroimaging cohort.(42) Antidepressant medications were also suggested to reduce dementia incidence in analyses from Kessing et al in datasets drawn from large Danish re…”
ResultCaruso, G., Grasso, M., Fidilio, A., Torrisi, S. A., Musso, N., Geraci, F., Tropea, M. R., Privitera, A., Tascedda, F., Puzzo, D., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.809541 · Cited by 49
“During the last decade, based on their ability to exert neuroprotection, the use of antidepressants to reduce the risk to develop AD has been proposed (Kessing et al., 2009; Kessing, 2012; Yuste et al., 2015; Bartels et al., 2018).”
BackgroundHampel, H., Vergallo, A., Caraci, F., Cuello, A. C., Lemercier, P., Vellas, B., Giudici, K. V., Baldacci, F., Hänisch, B., Haberkamp, M., et al. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108081 · Cited by 50
He, Y., Li, H., Huang, J., Huang, S., Bai, Y., Li, Y., & Huang, W. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211030181 · Cited by 61
“A longitudinal study including 755 nondepressed participants has confirmed that long-term SSRI treatment may delay progression from mild cognitive impairment (MCI) to Alzheimer's dementia (Bartels et al., 2018).”
BackgroundThe Post-amyloid Era in Alzheimer's Disease: Trust Your Gut Feeling
Osorio, C., Kanukuntla, T., Diaz, E., Jafri, N., Cummings, M., & Sfera, A. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00143 · Cited by 49
Depression in Alzheimer’s Disease: An Alternative Role for Selective Serotonin Reuptake Inhibitors?
Elsworthy, R. J., & Aldred, S. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180780 · Cited by 74
“Current research suggests that long-term treatment with SSRIs may delay the progression from MCI to AD [102, 103].”
Saggu, S., Bai, A., Aida, M., Rehman, H., Pless, A., Ware, D., Deák, F., Jiao, K., & Wang, Q. (2024) · GeroScience · doi:10.1007/s11357-024-01359-x · Cited by 55
Bucholc, M., Bauermeister, S., Kaur, D., McClean, P. L., & Todd, S. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12248 · Cited by 55
Zhou, C., Chao, F., Zhang, Y., Jiang, L., Zhang, L., Fan, J., Wu, Y., Dou, X., & Tang, Y. (2019) · Journal of Comparative Neurology · doi:10.1002/cne.24616 · Cited by 44
Antidepressant use and cognitive decline in patients with dementia: a national cohort study
Mo, M., Abzhandadze, T., Hoang, M. T., Sacuiu, S., Jurado, P. G., Pereira, J. B., Naia, L., Kele, J., Maioli, S., Xu, H., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-03851-3 · Cited by 45
Ceyzériat, K., Gloria, Y., Tsartsalis, S., Fossey, C., Cailly, T., Fabis, F., Millet, P., & Tournier, B. B. (2021) · Brain Communications · doi:10.1093/braincomms/fcab029 · Cited by 47
Metaxas, A., Anzalone, M., Vaitheeswaran, R., Petersen, S., Landau, A. M., & Finsen, B. R. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0491-2 · Cited by 45
“sion from mild cognitive impairment to AD [3].”
Antidepressants in Alzheimer’s Disease: A Focus on the Role of Mirtazapine
Correia, A. S., & Vale, N. (2021) · Pharmaceuticals · doi:10.3390/ph14090930 · Cited by 46
“In another study, the long-term use (over periods longer than four years) of SSRIs in patients with MCI was associated with slower progression to AD [56].”
BackgroundHuang, I.-C., Chang, T.-S., Chen, C., & Sung, J.-Y. (2022) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac054 · Cited by 41
“Bartels et al. (2018) suggested that using SSRI to treat patients with depression for more than 4 years was associated with a delay in cognitive dysfunction.”
MethodMental Health of Older Adults: A Global Perspective of Inequalities and Inadequacies
Baiyewu, O., Esan, O., & Elugbadebo, O. O. (2021) · Springer eBooks · doi:10.1007/978-3-030-57296-9_119 · Cited by 46
Gonzales, M. M., Samra, J., O’Donnell, A., Mackin, R. S., Salinas, J., Jacob, M. E., Satizabal, C. L., Aparicio, H. J., Thibault, E. G., Sanchez, J. S., et al. (2021) · Journal of Alzheimer's Disease · doi:10.3233/jad-210232 · Cited by 37
“Observational studies have produced conflicting findings with evidence of both increased [26] and lowered incident dementia risk [27, 28] associated with antidepressant use.”
BackgroundCognitive effects of vortioxetine in older adults: a systematic review
Bishop, M. M., Fixen, D. R., Linnebur, S. A., & Pearson, S. M. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211026796 · Cited by 39
Impact of psychotropic medications on cognition among older adults: a systematic review
Chandramouleeshwaran, S., Khan, W. U., Inglis, F., & Rajji, T. K. (2023) · International Psychogeriatrics · doi:10.1017/s1041610223000844 · Cited by 39
Schliep, K. C., Barbeau, W. A., Lynch, K. E., Sorweid, M. K., Varner, M. W., Foster, N. L., & Qeadan, F. (2022) · Biology of Sex Differences · doi:10.1186/s13293-022-00425-3 · Cited by 39
Some Candidate Drugs for Pharmacotherapy of Alzheimer’s Disease
Miziak, B., Błaszczyk, B., & Czuczwar, S. J. (2021) · Pharmaceuticals · doi:10.3390/ph14050458 · Cited by 37
Andries, E., Bosmans, J., Engelborghs, S., Cras, P. P., Vanderveken, O. M., Lammers, M. J. W., de Heyning, P. V., Rompaey, V. V., & Mertens, G. (2023) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2022.5046 · Cited by 38
Targeting Infectious Agents as a Therapeutic Strategy in Alzheimer’s Disease
Fülöp, T., Munawara, U., Larbi, A., Desroches, M., Rodrigues, S., Catanzaro, M., Guidolin, A., Khalil, A., Bernier, F., Barron, A. E., et al. (2020) · CNS Drugs · doi:10.1007/s40263-020-00737-1 · Cited by 36
Alterations and interactions of subcortical modulatory systems in Alzheimer's disease
Leko, M. B., Hof, P. R., & Šimić, G. (2021) · Progress in brain research · doi:10.1016/bs.pbr.2020.07.016 · Cited by 32
Nykamp, M. J., Zorumski, C. F., Reiersen, A. M., Nicol, G. E., Cirrito, J. R., & Lenze, E. J. (2021) · Pharmacopsychiatry · doi:10.1055/a-1686-9620 · Cited by 35
Dysregulation of serotonergic neurotransmission in Parkinson disease: A key duet
Khowdiary, M. M., Al-Kuraishy, H. M., Al-Gareeb, A. I., Albuhadily, A. K., Elhenawy, A. A., Babalghith, A. O., Shokr, M. M., Alexiou, A. T., Papadakis, M., & Batiha, G. E. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177419 · Cited by 28
He, J., Liu, R., Peng, Y.-M., Guo, Q., Zhu, L.-B., Lian, Y.-Z., Hu, B., Fan, H.-H., Zhang, X., & Zhu, J. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02097-z · Cited by 27
Yang, A., Wang, X.-L., Rui, H.-R., Luo, H., Pang, M., & Dou, X. (2020) · The journal of nutrition health & aging · doi:10.1007/s12603-020-1312-9 · Cited by 25
“Mild cognitive impairment (MCI) status remains a transitional period of time from normal aging to Alzheimer’s disease (AD) (1, 2).”
BackgroundAn update on antidepressant pharmacotherapy in late-life depression
Brender, R., Mulsant, B. H., & Blumberger, D. M. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1921736 · Cited by 26
“MCI who have a history of depression even after mood symptoms have resolved [35].”
BackgroundShindo, R., Tanifuji, T., Okazaki, S., Otsuka, I., Shirai, T., Mouri, K., Horai, T., & Hishimoto, A. (2023) · npj Aging · doi:10.1038/s41514-023-00117-1 · Cited by 27
Sex Differences in Depression as a Risk Factor for Alzheimer’s Disease: A Systematic Review
Underwood, E. A., Davidson, H., Azam, A. B., & Tierney, M. C. (2019) · Innovation in Aging · doi:10.1093/geroni/igz015 · Cited by 30
Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders
Khatri, D. K., Kadbhane, A., Patel, M., Nene, S., Atmakuri, S., Srivastava, S., & Singh, S. B. (2021) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2021.100022 · Cited by 26
Baek, M. S., Han, K., Kwon, H.-S., Lee, Y., Cho, H., & Lyoo, C. H. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.611446 · Cited by 27
“Moreover, the other study found the effect of selective serotonin-reuptake inhibitor (SSRI) treatment on the delayed progression in AD (46).”
BackgroundBaek, S.-H., Hong, G.-R., Min, D.-K., Kim, E., & Park, S.-K. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18157961 · Cited by 25
“[45] mentioned that higher symptoms of depression are likely to cause higher prevalence of dementia and that the BDNF enhanced by exercise helps relieves depression [46].”
BackgroundLaMonica, H. M., Hickie, I. B., Ip, J., Ireland, C., Mowszowski, L., English, A., Glozier, N., & Naismith, S. L. (2019) · International Psychogeriatrics · doi:10.1017/s1041610218002144 · Cited by 23
Virus-Induced Membrane Fusion in Neurodegenerative Disorders
Osorio, C. P., Sfera, A., Anton, J. J., Thomas, K. G., Andronescu, C. V., Li, E., Yahia, R., Avalos, A. G., & Kozlakidis, Z. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.845580 · Cited by 23
Exploring the Recent Trends in Management of Dementia and Frailty: Focus on Diagnosis and Treatment
Rahman, M. M., Mim, S. A., Islam, M. R., Parvez, A., Islam, F., Uddin, M. B., Rahaman, M. S., Shuvo, P. A., Ahmed, M., Greig, N. H., et al. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220408102051 · Cited by 26
Mechanisms and treatment of late-life depression
Alexopoulos, G. S. (2021) · Focus · doi:10.1176/appi.focus.19304 · Cited by 22
Little, M. O. (2018) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2018.07.001 · Cited by 23
Mathar, D., Abdoust, M. E., Tuszus, D., Marrenbach, T., & Peters, J. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010785 · Cited by 26
Reyna, N. C., Clark, B. J., Hamilton, D. A., & Pentkowski, N. S. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1251075 · Cited by 26
A Multifactor Approach to Mild Cognitive Impairment
Qarni, T., & Salardini, A. (2019) · Seminars in Neurology · doi:10.1055/s-0039-1678585 · Cited by 23
Loureiro, J., Stella, F., Pais, M., Radanovic, M., Canineu, P., Joaquim, H., Talib, L., & Forlenza, O. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.166 · Cited by 18
Severino, M., Sivasaravanaparan, M., Olesen, L. Ø., von Linstow, C. U., Metaxas, A., Bouzinova, E. V., Khan, A. M., Lambertsen, K. L., Babcock, A. A., Gramsbergen, J. B., et al. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.04.005 · Cited by 22
Niotis, K., Saperia, C., Saif, N., Carlton, C., & Isaacson, R. (2024) · Nature Mental Health · doi:10.1038/s44220-023-00191-0 · Cited by 21
“…(ω-3 PUFAs), as well as folate, vitamin E, carotenoids and flavonoids 81 . ω-3 PUFAs may be protective against AD by promoting proper clearance 127 Alzheimer’s Association Trajectory Report 128 Mdawar et al. 129 Nykamp et al. 130 Stress reduction via mindfulness training, meditation, periodic…”
InfluentialFan, K., Seah, B., Lu, Z., Wang, T., & Zhou, Y. (2024) · Aging & Mental Health · doi:10.1080/13607863.2024.2358079 · Cited by 22
“First, depression is also a risk factor for cognitive impairment, and it has been confirmed that depressive symptoms can increase cognition progression (Bartels et al., 2018; Zacková et al., 2021).”
Zhang, C., Wang, L., Xu, Y., Huang, Y., Huang, J., Zhu, J., Wang, W., Li, W., Sun, A., Li, X., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114347 · Cited by 21
Cognitive impairment and medial temporal lobe structure in young adults with a depressive episode
Donix, M., Haußmann, R., Helling, F., Zweiniger, A., Lange, J., Werner, A., Donix, K. L., Brandt, M., Linn, J., Bauer, M., et al. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.05.015 · Cited by 24
Cutuli, D., Giacovazzo, G., Decandia, D., & Coccurello, R. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1010169 · Cited by 19
“The use of SSRIs in AD patients is acknowledged to manage not only depressive symptoms but also contribute to preventing the exacerbation of cognitive decline, slowing down disease progression (112), and reducing conversion from MCI to AD (113).”
BackgroundMarquié, M., García‐Gutiérrez, F., Orellana, A., Montrreal, L., de Rojas, I., García‐González, P., Puerta, R., Olivé, C., Cano, A. C., Hernández, I., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021371 · Cited by 19
“Another study demonstrated that MCI patients with a history of depression presented a delay in progression to dementia after receiving treatment with selective serotonin reuptake inhibitors for several years [32].”
BackgroundDementia and depression: Biological connections with amyloid β protein
dos Santos, H. M., Bertollo, A. G., Mingoti, M. E. D., Grolli, R. E., Kreuz, K. M., & Ignácio, Z. M. (2024) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13996 · Cited by 26
“47 Studies have found changes in glutamate levels in depression and AD, indicating a dysfunction in the NMDA receptor signalling pathway.”
BackgroundNelson, J. C., Gandelman, J. A., & Mackin, R. S. (2024) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2024.08.015 · Cited by 21
Swann, P., Mirza-Davies, A., & O'Brien, J. T. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s385825 · Cited by 19
“For example, a range of different diagnostic criteria were used for AD, with some using standardized criteria including biomarkers, 93 and others a single score on a cognitive test.”
ResultInfluentialBouter, Y., & Bouter, C. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.883256 · Cited by 19
Tournier, M., Pambrun, É., Maumus‐Robert, S., Pariente, A., & Verdoux, H. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13380 · Cited by 21
Pirker-Kees, A., Dal-Bianco, P., & Schmidt, R. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181102 · Cited by 17
Samy, A. L., Kamaruzzaman, S. B., Krishnaswamy, S., & Low, W. Y. (2019) · Clinical Gerontologist · doi:10.1080/07317115.2019.1608611 · Cited by 17
Pierson, S. R., Kolling, L. J., James, T. D., Selvakumar, G. P., & Marcinkiewcz, C. A. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107171 · Cited by 17
Wang, H., Li, S., Zhang, J., Peng, W., Li, T., & Zhang, J. (2024) · European journal of medical research · doi:10.1186/s40001-024-02006-z · Cited by 18
“However, several studies have indicated that some selective serotonin reuptake inhibitors (SSRIs) have a positive effect on improving AD symptoms [19, 20].”
BackgroundKhoury, R., & Grossberg, G. T. (2018) · CNS Drugs · doi:10.1007/s40263-018-0590-9 · Cited by 17
Lin, C., Lee, S.-H., Huang, C., Wu, Y., Chang, Y.-X., Liu, H., Ng, S., Cheng, Y., Chiu, C., & Wu, S. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.01.205 · Cited by 16
Angelopoulou, E., Bougea, A. M., Hatzimanolis, A., Scarmeas, N., & Papageorgiou, S. G. (2024) · Cells · doi:10.3390/cells13131164 · Cited by 17
Current Diagnostic Challenges in Late-Life Depression and Neurocognitive Disorders
Adriani, B., Arena, J. F., Fioretti, A., Mancino, S., Sarno, F., Ferracuti, S., & CASALE, A. D. (2024) · Psychiatry International · doi:10.3390/psychiatryint5040061 · Cited by 20
Therapy Strategies for Late-life Depression: A Review
Piel, C., & Quante, A. (2023) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000678 · Cited by 17
Systems biology of Alzheimer’s Disease: a scoping review of key pathways and mechanisms
Bice, P. J., Nho, K. T., Ertekin‐Taner, N., & Saykin, A. J. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00934-4 · Cited by 18
“Similarly, Bartels et al. reported a three-year delay in conversion from MCI to AD among individuals treated long-term with SSRIs for depression compared to those using non-SSRI antidepressants, though the observational nature of this study limits causal interpretation [164].”
Depression interacts with allostatic load to predict cognitive decline in middle age
Perlman, G., Cogo‐Moreira, H., Wu, C., Herrmann, N., & Swardfager, W. (2022) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2022.105922 · Cited by 14
Ľupták, M., Fišar, Z., & Hroudová, J. (2023) · Antioxidants · doi:10.3390/antiox12061208 · Cited by 17
Diniz, B. S., Chen, Z., Steffens, D. C., Pilling, L. C., Nikolova, Y. S., Clifford, K. P., Fortinsky, R. H., Kuchel, G. A., & Kuo, C. (2025) · Nature Mental Health · doi:10.1038/s44220-025-00460-0 · Cited by 16
“…of these pathophysiological processes and moderate the risk of ADRD in individuals with MDD. Antidepressant treatment may have a mild effect on improving cognitive performance in individuals with MDD 53 , although they do not seem to have a robust effect preventing ADRD in individuals with MDD 54 .”
Parial, L. L., Leung, A. Y. M., Sumile, E. F., & Lam, S. C. (2021) · Geriatric Nursing · doi:10.1016/j.gerinurse.2021.09.013 · Cited by 13
Tian, J., Stucky, C. S., Wang, T., Muma, N. A., Johnson, M. A., & Du, H. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230072 · Cited by 14
“Moreover, serotonin-enhancing agents lower the production of amyloid-(cid:2) (A (cid:2) ) [17, 24], a key mediator of AD [25], and demonstrate promising effects in preventing the development of AD especially in individuals with depressive symptoms [22, 26].”
The temporal association between incident late‐life depression and incident dementia
Heser, K., Fink, A., Reinke, C., Wagner, M., & Doblhammer, G. (2020) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13220 · Cited by 14
Self-citationWang, Y., Li, M., Haughton, D., & Kazis, L. E. (2024) · PLoS ONE · doi:10.1371/journal.pone.0306270 · Cited by 16
“In clinical practice, to determine whether someone with MCI may convert to AD, a clinician rules out other causes that account for cognitive changes, such as depression and related medications that may be associated with conversion from MCI to AD [12].”
BackgroundNeurobiological and therapeutic landmarks of depression associated with Alzheimer’s disease dementia
Untu, I., Davidson, M., Stanciu, G. D., Rabinowitz, J., Dobrin, R., Vieru, D. S., & Tamba, B.-I. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1584607 · Cited by 17
Kostev, K., Bohlken, J., & Jacob, L. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190239 · Cited by 13
Qin, M., Wu, J., Zhou, Q., Liang, Z., & Su, Y. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.09.039 · Cited by 12
Li, W., Sun, L., Yue, L., & Xiao, S. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.10.028 · Cited by 12
Serotonin and amyloid deposition: A link between depression and Alzheimer’s disease?
Gründer, G., & Cumming, P. D. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15269 · Cited by 12
“Indeed, Kaplan–Meier analysis of data in the Alzheimer's Disease Neuroimaging Initiative (ADNI) database associated long-term (> four years) SSRI use with a three-year delay in conversion from mild cognitive impairment (MCI) to Alzheimer's disease (Bartels et al., 2018).”
BackgroundRamos‐Cejudo, J., Corrigan, J. K., Zheng, C., Swinnerton, K. N., Jacobson, S. R., La, J., Betensky, R. A., Osorio, R. S., Madanes, S., Pomara, N., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13853 · Cited by 11
“…Disease Neuroimaging Initiative (ADNI) suggested that long-term SSRI exposure may be associated with a delay in the progression from mild cognitive impairment (MCI) to AD by 3 years 29 ; however, no changes in cerebrospinal fluid AD marker levels were apparent in response to treatment in this case.”
BackgroundXu, J., Wang, F., Zang, C., Zhang, H., Niotis, K., Liberman, A. L., Stonnington, C. M., Ishii, M., Adekkanattu, P. M., Luo, Y., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-35258-6 · Cited by 11
Serrano, V. B., Montoya, J. L., Campbell, L. M., Sundermann, E. E., Iudicello, J. E., Letendre, S. L., Heaton, R. K., & Moore, D. J. (2021) · Journal of NeuroVirology · doi:10.1007/s13365-021-01001-y · Cited by 11
“The literature on the relationship between SSRIs and aMCI/AD is somewhat mixed, with some studies finding that SSRIs may be neuroprotective and delay progression of AD (Bartels et al. 2017) whereas others find that SSRI use is associated with increased risk of dementia (Kessing et al. 2009).”
Metadata
- Authors
- Bartels, C., Wagner, M., Wolfsgruber, S., Ehrenreich, H., Schneider, A., & Initiative, F. T. A. D. N.
- Affiliations
- University of Bonn (DE)
- Venue
- American Journal of Psychiatry
- Published
- 2018-03-01
- Volume
- 175
- Issue
- 3
- Pages
- 232-241
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2768441608
- Semantic Scholar
- 84cf627e767f53e0918c5ac480be02106899308f
- Cited by
- 202
- References
- 50
- Citations by year
- 2026: 12 · 2025: 25 · 2024: 26 · 2023: 26 · 2022: 29 · 2021: 34 · 2020: 15 · 2019: 19 · 2018: 15
- FWCI
- 11.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- DZNE Pub (publishedVersion)
- Max Planck Digital Library (submittedVersion)
- GRO (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- National Institutes of Health (5u01ag024904-10)
- National Institute on Aging (U01-AG-024904)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- selective serotonin reuptake inhibitors, citalopram, mild cognitive impairment, Alzheimer's disease, conversion to dementia, history of depression, cerebrospinal fluid biomarkers, amyloid-beta, APOE ε4, antidepressant treatment duration, Alzheimer's Disease Neuroimaging Initiative
- MeSH terms
- Aged, Alzheimer Disease, Depression, Humans, Risk Factors, Citalopram, Selective Serotonin Reuptake Inhibitors, Kaplan-Meier Estimate, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.